Tuesday, May 29, 2012
NCI Cancer Bulletin (May 29, 2012) – In a phase III clinical trial, the antipsychotic drug olanzapine (Zyprexa) was significantly more effective than metoclopramide (Reglan) in controlling chemotherapy-induced nausea and vomiting (CINV) that occurs in some patients despite preventive treatment for these side effects. (Olanzapine is approved by the Food and Drug Administration to treat schizophrenia and bipolar disorder.) Dr. Rudolph Navari of Indiana University School of Medicine-South Bend presented the results at a May 16 press briefing held in advance of the American Society of Clinical Oncology (ASCO) annual meeting.
The double-blinded randomized trial is the first study to demonstrate an effective treatment for “breakthrough” CINV, defined as nausea and vomiting that persist despite preventive treatments. About 30 to 40 percent of patients receiving certain chemotherapy drugs experience breakthrough CINV, which usually develops 2 to 4 days after treatment.
Dr. Navari and his colleagues studied 80 patients who developed breakthrough vomiting or nausea after treatment with chemotherapies that are known to induce vomiting, such as cisplatin, cyclophosphamide, and doxorubicin.
During the 72-hour follow-up period, 71 percent of patients receiving olanzapine had no vomiting, compared with 32 percent of patients receiving metoclopramide. Olanzapine prevented nausea in 67 percent of patients, versus 24 percent for metoclopramide. The differences between the two treatment groups were statistically significant, and neither drug caused severe side effects.
“The recommendation from ASCO and other international guidelines is to use your best antiemetics up front,” explained Dr. Navari. “Then, if patients develop breakthrough nausea and vomiting, there really haven’t been any good options.” Metoclopromide is often used in such cases, “but it hasn’t been that effective,” he said.
The results “are a great step forward for quality of life for our patients,” Dr. Sandra Swain, ASCO president-elect, said at the press briefing. For some patients, breakthrough CINV is so debilitating that they will “opt out of curative treatment,” she added.
November 23, 2013
Since its founding in 1997, Golfers Against Cancer has had one goal: to fund cancer research. Virtually all the money raised in GAC tournaments and events goes directly to cancer research organizations, including the CHRISTUS Stehlin Foundation.
August 2, 2013
The 14th Annual Luci Bonneau Memorial Striking Against Breast Cancer Mixed Doubles Bowling Tournament is one of the most prestigious doubles events in America. The tournament includes a Pro-Am - your chance to bowl with the pros to cure breast cancer!
October 19, 2013 | 7:00 p.m.
Get ready to disco and dance the night away at The Friends of CHRISTUS Stehlin Gala! Premiering “STAYIN’ ALIVE,” The Greatest Bee Gees Tribute Band with Members of the Houston Symphony Orchestra and America’s first Mash Up Group, “THE COMPANY MEN.”
May 4, 2013
On May 4th, 2013, young women will take the field for the first time in an exciting powder puff football game with teams comprised of some of best and brightest in Austin. The game is designed to bring the passion and spirit of young community leaders together to support Young Texans Against Cancer.
“The new facility for the CHRISTUS Stehlin Foundation is an appropriate setting for an organization that has made an enormous contribution to the ongoing battle against cancer.”
Sister Lillian Anne Healy, CCVI,
Congregational Leader for Sister of Charity of the Incarnate Word
CHRISTUS Stehlin Foundation for Cancer Research will join CHRISTUS St. Catherine and CHRISTUS St. John in a new partnership with Houston Methodist.
There are currently 13.7 million cancer survivors in the United States and the number is expected to rise by 31 percent to 18 million by 2022, according to a new report. >> Click article title for more.